Cargando…
Confronting TB/HIV in the era of increasing anti-TB drug resistance
HIV associated TB is a major public health problem. In 2006, it was estimated that there were over 700,000 people who suffered from HIV associated TB, of whom about 200, 000 have died. The burden of HIV associated TB is greatest in Sub-Saharan Africa where the TB epidemic is primarily driven by HIV....
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The International AIDS Society
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588552/ https://www.ncbi.nlm.nih.gov/pubmed/19014421 http://dx.doi.org/10.1186/1758-2652-11-6 |
_version_ | 1782160950064840704 |
---|---|
author | Chakaya, Jeremiah Getahun, Haileyesus Granich, Reuben Havlir, Diane |
author_facet | Chakaya, Jeremiah Getahun, Haileyesus Granich, Reuben Havlir, Diane |
author_sort | Chakaya, Jeremiah |
collection | PubMed |
description | HIV associated TB is a major public health problem. In 2006, it was estimated that there were over 700,000 people who suffered from HIV associated TB, of whom about 200, 000 have died. The burden of HIV associated TB is greatest in Sub-Saharan Africa where the TB epidemic is primarily driven by HIV. There has been steady progress made in reducing the burden of HIV in TB patients with an increasing number of TB patients tested for HIV and provided with cotrimoxazole preventive therapy (CPT) and anti-retroviral treatment (ART). Less progress is being made to reduce the burden of TB in people living with HIV. The number of HIV infected persons reported to have been screened for TB was less than 1% while Isoniazid preventive therapy was reported to have been provided to less than 0.1% of eligible persons in 2006. A major push is urgently needed to accelerate the implementation of three important interventions. The three are Intensified TB Screening (ICF) among people living with HIV, the provision of Isoniazid Preventive Therapy (IPT) and TB Infection Control(IC). These interventions are best carried out by HIV control programmes which should therefore be encouraged to take greater responsibility in implementing these interventions. |
format | Text |
id | pubmed-2588552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | The International AIDS Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-25885522008-11-28 Confronting TB/HIV in the era of increasing anti-TB drug resistance Chakaya, Jeremiah Getahun, Haileyesus Granich, Reuben Havlir, Diane J Int AIDS Soc Review HIV associated TB is a major public health problem. In 2006, it was estimated that there were over 700,000 people who suffered from HIV associated TB, of whom about 200, 000 have died. The burden of HIV associated TB is greatest in Sub-Saharan Africa where the TB epidemic is primarily driven by HIV. There has been steady progress made in reducing the burden of HIV in TB patients with an increasing number of TB patients tested for HIV and provided with cotrimoxazole preventive therapy (CPT) and anti-retroviral treatment (ART). Less progress is being made to reduce the burden of TB in people living with HIV. The number of HIV infected persons reported to have been screened for TB was less than 1% while Isoniazid preventive therapy was reported to have been provided to less than 0.1% of eligible persons in 2006. A major push is urgently needed to accelerate the implementation of three important interventions. The three are Intensified TB Screening (ICF) among people living with HIV, the provision of Isoniazid Preventive Therapy (IPT) and TB Infection Control(IC). These interventions are best carried out by HIV control programmes which should therefore be encouraged to take greater responsibility in implementing these interventions. The International AIDS Society 2008-11-06 /pmc/articles/PMC2588552/ /pubmed/19014421 http://dx.doi.org/10.1186/1758-2652-11-6 Text en Copyright ©2008 Chakaya et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Chakaya, Jeremiah Getahun, Haileyesus Granich, Reuben Havlir, Diane Confronting TB/HIV in the era of increasing anti-TB drug resistance |
title | Confronting TB/HIV in the era of increasing anti-TB drug resistance |
title_full | Confronting TB/HIV in the era of increasing anti-TB drug resistance |
title_fullStr | Confronting TB/HIV in the era of increasing anti-TB drug resistance |
title_full_unstemmed | Confronting TB/HIV in the era of increasing anti-TB drug resistance |
title_short | Confronting TB/HIV in the era of increasing anti-TB drug resistance |
title_sort | confronting tb/hiv in the era of increasing anti-tb drug resistance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588552/ https://www.ncbi.nlm.nih.gov/pubmed/19014421 http://dx.doi.org/10.1186/1758-2652-11-6 |
work_keys_str_mv | AT chakayajeremiah confrontingtbhivintheeraofincreasingantitbdrugresistance AT getahunhaileyesus confrontingtbhivintheeraofincreasingantitbdrugresistance AT granichreuben confrontingtbhivintheeraofincreasingantitbdrugresistance AT havlirdiane confrontingtbhivintheeraofincreasingantitbdrugresistance |